Roche, Trimeris Plan to Make Antiretroviral Drug Fuzeon More Widely Available
April 16, 2004
The manufacturers of the antiretroviral drug Fuzeon have announced that the drug soon will be available in retail and specialty pharmacies, the Raleigh News & Observer reports (Vollmer, Raleigh News & Observer, 4/15). Swiss drug maker Roche and U.S. biotechnology company Trimeris jointly developed Fuzeon, which is in a class of drugs called fusion inhibitors and is designed for HIV/AIDS patients who have failed to respond to other medications (Kaiser Daily HIV/AIDS Report, 2/5). In order to make the drug available to patients, physicians previously had to fax a prescription to the drug's lone mail-order distributor, according to the News & Observer (Raleigh News & Observer, 4/15). However, Roche is expanding its manufacturing process to allow physicians to write prescriptions for Fuzeon that patients can take directly to pharmacies, Roche spokesperson Pamela Van Houton said, according to the AP/Long Island Newsday (Johnson, AP/Long Island Newsday, 4/15). Trimeris Vice President of Commercial Operations Walter Capone said that making the drug more widely available will "make it more convenient for patients" (Raleigh News & Observer, 4/15). Fuzeon will be available beginning April 26 in specialty and retail pharmacies, according to the AP/Newsday (AP/Long Island Newsday, 4/15).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.